iX Biopharma Ltd. (SGX:42C)
Singapore · Delayed Price · Currency is SGD 0.4050
-0.0050 (-1.22%)
Aug 28, 2026, 5:07 PM SGT
iX Biopharma Income Statement
Financials in millions SGD. Fiscal year is July - June.
Millions SGD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Revenue | 6.85 | 7.77 | 5.96 | 5.91 | 14.39 |
Revenue Growth | -11.77% | 30.34% | 0.78% | -58.91% | 724.64% |
Cost of Revenue | 4.42 | 5.73 | 4.91 | 3.59 | 2.1 |
Gross Profit | 2.43 | 2.04 | 1.05 | 2.32 | 12.29 |
Selling, General & Admin | 9.45 | 6.69 | 6.71 | 9.04 | 9.46 |
Research & Development | 2.49 | 1.64 | 1.73 | 2.82 | 2.33 |
Operating Expenses | 12 | 8.33 | 8.54 | 11.86 | 11.79 |
Operating Income | -9.56 | -6.29 | -7.5 | -9.54 | 0.5 |
Interest Expense | -0.69 | -0.33 | -0.44 | -0.27 | -0.2 |
Interest & Investment Income | - | 0.02 | 0.03 | 0.01 | - |
Currency Exchange Gain (Loss) | 2.55 | -3.4 | 0.08 | -2.77 | -1.91 |
Other Non Operating Income (Expenses) | 0.08 | -0.14 | 0.35 | 1.12 | 0.74 |
EBT Excluding Unusual Items | -7.62 | -10.14 | -7.47 | -11.46 | -0.88 |
Impairment of Goodwill | -0.29 | - | - | - | - |
Gain (Loss) on Sale of Investments | - | -0.01 | -2.51 | 1.74 | -3.26 |
Asset Writedown | -0.08 | - | - | - | - |
Other Unusual Items | - | - | - | 0.01 | 0.04 |
Pretax Income | -7.98 | -10.14 | -9.99 | -9.71 | -4.1 |
Income Tax Expense | 0.01 | 0 | 0.81 | -0.09 | 0.5 |
Earnings From Continuing Operations | -7.99 | -10.14 | -10.79 | -9.62 | -4.6 |
Net Income | -7.99 | -10.14 | -10.79 | -9.62 | -4.6 |
Net Income to Common | -7.99 | -10.14 | -10.79 | -9.62 | -4.6 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 965 | 877 | 767 | 765 | 746 |
Shares Outstanding (Diluted) | 965 | 877 | 767 | 765 | 746 |
Shares Change | 10.08% | 14.25% | 0.33% | 2.51% | 7.60% |
EPS (Basic) | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
EPS (Diluted) | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -7.62 | -3.96 | -6.83 | -8.36 | 2.92 |
Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 |
Gross Margin | 35.52% | 26.27% | 17.59% | 39.24% | 85.41% |
Operating Margin | -139.52% | -80.92% | -125.78% | -161.41% | 3.48% |
Profit Margin | -116.64% | -130.56% | -181.14% | -162.61% | -31.95% |
Free Cash Flow Margin | -111.21% | -50.97% | -114.57% | -141.30% | 20.31% |
EBITDA | -9.19 | -5.87 | -7.08 | -9.04 | 1.15 |
EBITDA Margin | -134.10% | -75.59% | -118.88% | -152.93% | 7.99% |
D&A For EBITDA | 0.37 | 0.41 | 0.41 | 0.5 | 0.65 |
EBIT | -9.56 | -6.29 | -7.5 | -9.54 | 0.5 |
EBIT Margin | -139.51% | -80.92% | -125.78% | -161.41% | 3.48% |